Intellia Therapeutics, Inc. (NTLA)
11.21
+0.05
(+0.45%)
USD |
NASDAQ |
Oct 23, 16:00
11.15
-0.06
(-0.54%)
After-Hours: 20:00
Intellia Therapeutics Enterprise Value : 1.205B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 1.205B |
| October 22, 2026 | 1.198B |
| October 21, 2026 | 1.267B |
| October 20, 2026 | 1.293B |
| October 19, 2026 | 1.257B |
| October 16, 2026 | 1.235B |
| October 15, 2026 | 1.223B |
| October 14, 2026 | 1.236B |
| October 13, 2026 | 1.303B |
| October 12, 2026 | 1.397B |
| October 09, 2026 | 1.466B |
| October 08, 2026 | 1.400B |
| October 07, 2026 | 1.275B |
| October 06, 2026 | 1.368B |
| October 05, 2026 | 1.421B |
| October 02, 2026 | 1.352B |
| October 01, 2026 | 1.333B |
| September 30, 2026 | 1.324B |
| September 29, 2026 | 1.320B |
| September 28, 2026 | 1.235B |
| September 25, 2026 | 1.281B |
| September 24, 2026 | 1.338B |
| September 23, 2026 | 1.362B |
| September 22, 2026 | 1.412B |
| September 21, 2026 | 1.347B |
| Date | Value |
|---|---|
| September 18, 2026 | 1.335B |
| September 17, 2026 | 1.352B |
| September 16, 2026 | 1.244B |
| September 15, 2026 | 1.226B |
| September 14, 2026 | 1.298B |
| September 11, 2026 | 1.279B |
| September 10, 2026 | 1.306B |
| September 09, 2026 | 1.345B |
| September 08, 2026 | 1.419B |
| September 04, 2026 | 1.419B |
| September 03, 2026 | 1.411B |
| September 02, 2026 | 1.422B |
| September 01, 2026 | 1.412B |
| August 31, 2026 | 1.418B |
| August 28, 2026 | 1.438B |
| August 27, 2026 | 1.471B |
| August 26, 2026 | 1.482B |
| August 25, 2026 | 1.527B |
| August 24, 2026 | 1.394B |
| August 21, 2026 | 1.433B |
| August 20, 2026 | 1.377B |
| August 19, 2026 | 1.495B |
| August 18, 2026 | 1.260B |
| August 17, 2026 | 1.328B |
| August 14, 2026 | 1.303B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 8.696B |
| Beam Therapeutics, Inc. | 1.578B |
| Prime Medicine, Inc. | 680.71M |
| 10X Genomics, Inc. | 8.848B |
| Moderna, Inc. | 75.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -106.63M |
| Revenue (Quarterly) | 7.659M |
| Total Expenses (Quarterly) | 114.29M |
| EPS Diluted (Quarterly) | -0.7989 |
| Gross Profit Margin (Quarterly) | 72.58% |
| Profit Margin (Quarterly) | -1.39K% |
| Earnings Yield | -29.95% |
| Normalized Earnings Yield | -29.92 |